Folotyn for Non-Hodgkin's Lymphoma Arlington VA

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

STE 400
(703) 280-5390
8503 Arlington Blvd
Fairfax, VA
Business
Fairfax Northern Virginia Hematology & Oncolo
Specialties
Oncology

Data Provided by:
Sung Ae Lee, MD
(918) 494-2013
2150 Pennsylvania Avenue North West Acc 3rd
Washington, DC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Female
Education
Medical School: Yonsei Univ, Coll Of Med, Sudai-Moon-Ku, Seoul, So Korea
Graduation Year: 1963
Hospital
Hospital: St Francis Hospital, Tulsa, Ok
Group Practice: Therapeutic Radiology Inc

Data Provided by:
James Ahlgren
(202) 741-2210
2150 Pennsylvania Ave Nw
Washington, DC
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
John Milburn Jessup, MD
(202) 687-5277
PO Box 571467-RM
Washington, DC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: New York Med Coll, Valhalla Ny 10595
Graduation Year: 1972

Data Provided by:
Bruce Robert Kressel, MD
(202) 293-5382
2141 K St NW Ste H707
Washington, DC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Tufts Univ Sch Of Med, Boston Ma 02111
Graduation Year: 1973

Data Provided by:
Nelson G Kalil, MD
(301) 774-6136
18111 Prince Philip Dr
Olney, MD
Business
Community Hematology Oncology Practicioners
Specialties
Oncology

Data Provided by:
James H Simon, MD
2150 Pennsylvania Ave NW
Washington, DC
Specialties
Oncology (Cancer), Radiation Oncology, General Practice
Gender
Male
Education
Medical School: Univ Of Ia Coll Of Med, Iowa City Ia 52242
Graduation Year: 1992

Data Provided by:
Ari Daniel Fishman, MD
(202) 293-5382
2141 K St NW Ste 707
Washington, DC
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Education
Medical School: Tel Aviv Univ, Sackler Fac Of Med, Tel Aviv, Israel
Graduation Year: 1995
Hospital
Hospital: George Washington Univ Hosp, Washington, Dc
Group Practice: Washington Oncology Ctr

Data Provided by:
Dr.Henry Fox
(202) 296-2440
2440 M St NW # 801
Washington, DC
Gender
M
Education
Medical School: Stanford Univ Sch Of Med
Year of Graduation: 1978
Speciality
Oncologist
General Information
Accepting New Patients: Yes
RateMD Rating
3.5, out of 5 based on 2, reviews.

Data Provided by:
Jack Jacoub, MD
(202) 741-2478
2121 Eye St NW,
Washington, DC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com